** Shares of gene-sequencing equipment maker Illumina ILMN.O fall 2.7% to $94.6
** Bernstein analysts say Roche's ROG.S new gene sequencing device designed to decode diseases such as cancer, immune disorders and neurodegenerative diseases outperforms ILMN's devices
** ROG unveiled the device on Thursday, featuring gene sequencing capabilities that provides detailed insights into genetics, genomics and cell biology
** ILMN shares had closed down 5.6% on Thursday, following the news
** Bernstein raises questions about the accuracy of the ROG device but said it could be a serious threat to ILMN in some applications
** ILMN has fallen 24.8% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。